

The 15th Best of ASCO20 Virtual

July 10 - 11, 2020 | Live Webinar Sessions



Organized by **The Lebanese Society of Medical Oncology (LSMO)**
Licensed by **The American Society of Clinical Oncology (ASCO)**

Endorsed by **The Arab Medical Association Against Cancer (AMAAC)**

Organized by LSMO (Lebanese Society of Medical Oncology)

Licensed by ASCO (American Society of Clinical Oncology)

Endorsed by The Arab Medical Association Against Cancer (AMAAC)

Chairs:

Chairperson: **Nizar Bitar, MD - LSMO President**

Co-Chairperson: **Roger Khater, MD - Nagi El Saghir, MD, FACP, FASCO**

Planning Committee:

Nizar Bitar, MD

Nagi S. El Saghir, MD

Roger Khater, MD

Joseph Makdessi, MD

Guest Speakers

International Speakers:

Ghassan Abou Alfa, MD (New York, USA) - Ahmad Awada, MD (Brussels, Belgium) - Etienne Brain, MD (Paris, France)

Toni Choueiri, MD (Boston, USA) - Ismail Jatoi, MD (Texas, USA) - Eileen O'Reilly, MD (New York, USA)

Regional Speakers:

Hikmat Abdel-Razek, MD (Amman, Jordan) - Sana Al-Sukhun, MD (Amman, Jordan) - Hamdy Azim, MD (Cairo, Egypt)

AbdelRahman Jazieh, MD (Riyadh, KSA) - Sami Khatib, MD (Amman, Jordan)

Lebanese Speakers:

Thérèse Abi Nasr, MD - Hazem Assi, MD - Rita Assi, MD - Tarek Assi, MD - David Atallah, MD - Nizar Bitar, MD

Jean El Cheikh, MD - Nagi El Saghir, MD - Georges Farha, MD - Antoine Finianos, MD - Marwan Ghosn, MD

Mohammad Bahjat Haidar, MD - Ahmad Ibrahim, MD - Khaled Ibrahim, MD - Fadi Karak, MD - Joseph Kattan, MD

Fadlo Khuri, MD - Joseph Makdessi, MD - Marcel Massoud, MD - Walid Moukaddem, MD - Deborah Mukherji, MD

Muhieddine Seoud, MD - Ali Shamseddine, MD - Sally Temraz, MD - Arafat Tfayli, MD - Bassem Youssef, MD

FRIDAY, JULY 10, 2020**10:30 - 11:00 Opening Ceremony****11:00 - 11:50 Breast Cancer | Local/Regional/Adjuvant**

Speakers: Ismail Jatoui, MD (USA) - Nagi El Saghir, MD (Lebanon)
Ahmad Awada, MD (Belgium)

Chairs:

11:00 - 11:10 ■ Abstract LBA2: A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).

(Seema Khan, MD, FACS, MPH)

Presented by Ismail Jatoui, MD

11:10 - 11:20 ■ Abstract 500: Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).

(Nadia Harbeck, MD)

Presented by Nagi El Saghir, MD

11:20 - 11:30 ■ Abstract 504: ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2-BC) in postmenopausal (PM) women: Alliance A011106.

(Cynthia Ma, MD, PhD)

Presented by Ahmad Awada, MD

11:30 - 11:40 ■ Abstract 506: MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.

(Fatima Cardoso, MD)

Presented by Ahmad Awada, MD

11:40 - 11:50 Q & A

FRIDAY, JULY 10, 2020**11:50 - 12:40 Breast Metastatic**

Speakers: Etienne Brain, MD (France) - Sanaa Al-Sukhun, MD (Jordan)
Hamdy Azim, MD (Egypt)

Chairs:

11:50 - 12:00 ■ **Abstract 1000:** KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

(Javier Cortes, MD, PhD)

Presented by Etienne Brain, MD

12:00 - 12:10 ■ **Abstract 1002:** TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

(Nadine Tung, MD)

Presented by Etienne Brain, MD

12:10 - 12:20 ■ **Abstract 1004:** A randomized, open-label, phase III trial of pertuzumab retreatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study.

(Yutaka Yamamoto, MD, PhD)

Presented by Sanaa Al-Sukhun, MD

12:20 - 12:30 ■ **Abstract 1007:** PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.

(Antonio Llombart-Cussac, MD)

Presented by Hamdy Azim, MD

12:30 - 12:40 Q & A

FRIDAY, JULY 10, 2020**12:40 - 12:55 BREAK****12:55 - 13:10 Health care Delivery / Cancer prevention/ Genetics**

Speaker: Hikmat Abdel-Razek, MD (Jordan)

Chairs:

12:55 - 13:05 ■ **Abstract 1508:** Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT).
([Susan M. Domchek](#))
Presented by Hikmat Abdel-Razek, MD

13:05 - 13:10 Q & A

13:10 - 13:35 Health Services / Quality Improvements

Speakers: Nizar Bitar, MD (Lebanon) - Sami Khatib, MD (Jordan)

Chairs:

13:10 - 13:20 ■ **Abstract LBA110:** Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19).
([Jeremy Warner MD](#))
Presented by Nizar Bitar, MD

13:20 - 13:30 ■ **Abstract LBA111:** Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.
([Leora Horn, MD](#))
Presented by Sami Khatib, MD

13:30 - 13:35 Q & A

FRIDAY, JULY 10, 2020

13:35 - 14:05 CNS Tumors

Speaker: Tarek Assi, MD (Lebanon)

Chairs:

13:35 - 13:45 ■ **Abstract 2500:** Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C.

[\(Kazuhiko Mishima\)](#)**Presented by Tarek Assi, MD**

13:45 - 13:55 ■ **Abstract 2501:** Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).

[\(Antonio Marcilio Padula Omuro\)](#)**Presented by Tarek Assi, MD**

13:55 - 14:05 Q & A

14:05 - 14:30 BREAK

14:30 - 15:20 GI: Colorectal and Anals

Speakers: Eileen O'Reilly, MD (USA) - Ghassan Abou Alfa, MD (USA)

Sally Temraz, MD (Lebanon)

Chairs:

14:30 - 14:40 ■ **Abstract LBA4:** Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study

[\(Thierry Andre, MD\)](#)**Presented by Eileen O'Reilly, MD**

14:40 - 14:50 ■ **Abstract 4001:** Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

[\(Scott Kopetz, MD, PhD\)](#)**Presented by Ghassan Abou Alfa, MD**

FRIDAY, JULY 10, 2020

14:50 - 15:00 ■ **Abstract 4000:** A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

(**Salvatore Siena, MD**)

Presented by Sally Temraz, MD

15:00 - 15:10 ■ **Abstract 4004:** Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.

(**Alberto F. Sobrero, MD**)

Presented by Eileen O'Reilly, MD

15:10 - 15:20 Q & A

15:20 - 16:10 GI Malignancies: GE J /Pancreas/ Hepatobiliary

Speakers: Ali Shamseddine, MD (Lebanon) - Eileen O'Reilly, MD (USA)
Ghassan Abou Alfa, MD (USA)

Chairs:

15:20 - 15:30 ■ **Abstract 4500:** Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010.

(**Howard Safran, MD**)

Presented by Ali Shamseddine, MD

15:30 - 15:40 ■ **Abstract 4504:** SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinix versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).

(**Davendra Sohal, MD, MPH**)

Presented by Eileen O'Reilly, MD

15:40 - 15:50 ■ **Abstract 4508:** Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

(**Robin Kelley, MD**)

Presented by Ghassan Abou Alfa, MD

FRIDAY, JULY 10, 2020

15:50 - 16:00 ■ **Abstract 4501:** Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion-A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

(**Salah-Eddin Al-Batran, MD**)

Presented by Ghassan Abou Alfa, MD

16:00 - 16:10 Q & A

16:25 - 17:15 GU: Kidney/ Bladder

Speakers: Toni Choueiri, MD (USA) - Marwan Ghosn, MD (Lebanon)

Chairs:

16:25 - 16:35 ■ **Abstract LBA1:** Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.

(**Thomas Powles, MD, PhD, FCRP**)

Presented by Toni Choueiri, MD

16:35 - 16:45 ■ **Abstract 5001:** Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

(**Elizabeth Plimack, MD, MS**)

Presented by Toni Choueiri, MD

16:45 - 16:55 ■ **Abstract 5006:** Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).

(**Michael Atkins, MD**)

Presented by Toni Choueiri, MD

16:55 - 17:05 ■ **Abstract 5000:** IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).

(**Maha Hussain, MD, FACP, FASCO**)

Presented by Marwan Ghosn, MD

17:05 - 17:15 Q & A

FRIDAY, JULY 10, 2020

17:15 - 18:05 GU: Prostate and Penile

Speakers: Joseph Kattan, MD (Lebanon) - Joseph Makdessi, MD (Lebanon)
Deborah Mukherji, MD (Lebanon) - Mohammad Bahjat Haidar, MD (Lebanon)

Chairs:

17:15 - 17:25 ■ **Abstract 5515:** Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

(Cora Sternberg, MD, FACP)

Presented by Joseph Kattan, MD

17:25 - 17:35 ■ **Abstract 5514:** Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).

(Karim Fizazi, MD, PhD)

Presented by Joseph Makdessi, MD

17:35 - 17:45 ■ **Abstract 5516:** Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

(Eric Small, MD, FASCO)

Presented by Deborah Mukherji, MD

17:45 - 17:55 ■ **Abstract 5501:** Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).

(Michael Morris, MD)

Presented by Mohammad Bahjat Haidar, MD

17:55 - 18:05 Q & A

SATURDAY, JULY 11, 2020

09:00 - 09:40 GYN Malignancies

Speakers: David Atallah, MD (Lebanon) - Muhieddine Seoud, MD (Lebanon)
Chairs:

09:00 - 09:10 ■ **Abstract 6000:** Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.
(Andreas Du Bois, MD, PhD)
Presented by David Atallah, MD

09:10 - 09:20 ■ **Abstract 6002:** Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
(Andrea Poveda, MD)
Presented by Muhieddine Seoud, MD

09:20 - 09:30 Q & A

09:40 - 10:00 Hematological Malignancies / Leukemia/ MDS/ BMT

Speakers: Rita Assi, MD (Lebanon) - Ahmad Ibrahim, MD (Lebanon)
Chairs:

09:30 - 09:40 ■ **Abstract 7500:** Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
(Curtis Andrew Lachowicz, MD)
Presented by Rita Assi, MD

09:40 - 09:50 ■ **Abstract 7501:** Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).
(Courtney Denton Dinardo, MD)
Presented by Ahmad Ibrahim, MD

09:50 - 10:00 Q & A

SATURDAY, JULY 11, 2020

10:10 - 10:30 Hematological Malignancies: Lymphoma / CLL

Speakers: Jean El Cheikh, MD (Lebanon) - Thérèse Abi Nasr, MD (Lebanon)

Chairs:

10:00 - 10:10 ■ **Abstract 8005:** KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

(John Kuruvilla, MD)

Presented by Jean El Cheikh, MD

10:10 - 10:20 ■ **Abstract 8004:** A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter's syndrome.

(Matthew Davids, MD)

Presented by Thérèse Abi Nasr, MD

10:20 - 10:30 Q & A

10:30 - 10:45 BREAK

10:45 - 11:15 Hematological Malignancies - Plasma Cell Dyscrasia

Speakers: Khaled Ibrahim, MD (Lebanon) - Walid Moukaddem, MD (Lebanon)

Chairs:

10:45 - 10:55 ■ **Abstract LBA3:** Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

(Shaji Kumar, MD)

Presented by Khaled Ibrahim, MD

10:55 - 11:05 ■ **Abstract 8501:** Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.

(Meletios Dimopoulos, MD)

Presented by Walid Moukaddem, MD

11:05 - 11:15 Q & A

SATURDAY, JULY 11, 2020

11:15 - 11:45 Head Neck Cancers

Speakers: George Farha, MD (Lebanon) - Bassem Youssef, MD (Lebanon)

Chairs:

11:15 - 11:25 ■ **Abstract 6500:** Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).

(Robert Ferris, MD, PhD, FACS)

Presented by George Farha, MD

11:25 - 11:35 ■ **Abstract 6502:** Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).

(Naomi Kiyota, MD, PhD)

Presented by Bassem Youssef, MD

11:35 - 11:45 Q & A

11:45 - 12:35 Lung Cancer: NSCLC-Regional/ SCLC

Speakers: Fadlo Khuri, MD (Lebanon) - Arafat Tfayli, MD (Lebanon) - Fadi Karak, MD (Lebanon)

Chairs:

11:45 - 11:55 ■ **Abstract LBA5:** Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

(Roy S. Herbst, MD, PhD)

Presented by Fadlo Khuri, MD

11:55 - 12:05 ■ **Abstract 9005:** CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation - Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.

(Yi-Long Wu, FACS)

Presented by Fadlo Khuri, MD

12:05 - 12:15 ■ **Abstract 9002:** Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study.

(Luis Paz-Ares, MD, PhD)

Presented by Arafat Tfayli, MD

SATURDAY, JULY 11, 2020

12:15 - 12:25 ■ **Abstract 9001:** KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
([Charlie Rudin, MD, PhD](#))
Presented by Fadi Karak, MD

12:25 - 12:35 Q & A

12:35 - 12:50 BREAK**12:50 - 13:20 Lung Cancer: NSCLC-Metastatic**

Speaker: AbdelRahman Jazieh, MD (KSA)

Chairs:

12:50 - 13:00 ■ **Abstract 9501:** Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs chemo (4 cycles) as first-line (1L) treatment for stage IV or recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
([Martin Reck, MD, PhD](#))
Presented by AbdelRahman Jazieh, MD

13:00 - 13:10 ■ **Abstract 9506:** NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
([Makoto Maemondo, MD, PhD](#))
Presented by AbdelRahman Jazieh, MD

13:10 - 13:20 Q & A

13:20 - 13:50 Melanoma/ Skin cancers

Speaker: Ahmad Awada, MD (Belgium) - Hazem Assi, MD (Lebanon)

Chairs:

13:20 - 13:30 ■ **Abstract 10004:** Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.
([Daniel Olson, MD](#))
Presented by Ahmad Awada, MD

SATURDAY, JULY 11, 2020

13:30 - 13:40 ■ **Abstract 10005:** Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
(Ines Pires Da Silva, MD, PhD)
Presented by Hazem Assi, MD

13:40 - 13:50 Q & A

13:50 - 14:20 Symptoms and Survivorship

Speakers: Marcel Massoud, MD (Lebanon) - Antoine Finianos, MD (Lebanon)
Chairs:

13:50 - 14:00 ■ **Abstract 12009:** A geriatric assessment (GA) intervention to reduce treatment toxicity in older patients with advanced cancer: A University of Rochester Cancer Center NCI community oncology research program cluster randomized clinical trial (CRCT).
(Supriya Gupta Mohile, MD, MS, FASCO)
Presented by Marcel Massoud, MD

14:00 - 14:10 ■ **Abstract 12000:** Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML).
(Areej El-Jawahri, MD)
Presented by Antoine Finianos, MD

14:10 - 14:20 Q & A

Organized by:



LEBANON

4th Floor, Qubic Center
Daoud Ammoun Street
Horsh Tabet - Sin El Fil
P.O. Box: 90-361 Beirut
Tel: +961 1 510880/1/2/3
Mobile: +961 71 103123

UAE

DMCC Business Centre
Almas Tower
Jumeirah Lakes
Dubai, United Arab Emirates
Unit No: 3820
Mobile: +971 50 9110475

KUWAIT

Mezzanine floor,
Aliya Complex
Salem Al Mubarak St
Block 2, Salmiya - Kuwait
Tel: +965 6556 7669



infomed@infomedweb.com | www.infomedweb.com